Drug Patents owned by Apgdi

1. Drug name - MYRBETRIQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(6 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(1 year, 1 month from now)

CN1136193C APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

CN1218045A APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

CN1575287A APGDI Acetyl-Or -Type Crystal Of Aniline Derivative
Oct, 2022

(a month from now)

CN1243740C APGDI Acetyl-Or -Type Crystal Of Aniline Derivative
Oct, 2022

(a month from now)

EP1028111A4 APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

EP1028111A1 APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

EP1028111B1 APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

EP2298752A1 APGDI Alpha-Form Or Beta-Form Crystal Of Acetanilide Derivative
Oct, 2022

(a month from now)

EP2298752B1 APGDI Alpha-Form Or Beta-Form Crystal Of Acetanilide Derivative
Oct, 2022

(a month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE44872 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient Nov, 2023

(1 year, 1 month from now)

US8835474 APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient Nov, 2023

(1 year, 1 month from now)

US7982049 APGDI α-form or β-form crystal of acetanilide derivative Nov, 2023

(1 year, 1 month from now)

US8835474

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient May, 2024

(1 year, 7 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

USRE44872

(Pediatric)

APGDI Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient May, 2024

(1 year, 7 months from now)

US8772315 APGDI Pharmaceutical composition for treating overactive bladder Oct, 2028

(6 years from now)

US8772315

(Pediatric)

APGDI Pharmaceutical composition for treating overactive bladder Apr, 2029

(6 years from now)

US10842780 APGDI Pharmaceutical composition for modified release Sep, 2029

(7 years from now)

US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release Mar, 2030

(7 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: For the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG TABLET, EXTENDED RELEASE;ORAL Prescription
50MG TABLET, EXTENDED RELEASE;ORAL Prescription

2. Drug name - MYRBETRIQ GRANULES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6346532 APGDI Amide derivatives or salts thereof
Mar, 2022

(6 months ago)

US7342117 APGDI α-form or β-form crystal of acetanilide derivative
Nov, 2023

(1 year, 1 month from now)

CN1136193C APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

CN1218045A APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

CN1575287A APGDI Acetyl-Or -Type Crystal Of Aniline Derivative
Oct, 2022

(a month from now)

CN1243740C APGDI Acetyl-Or -Type Crystal Of Aniline Derivative
Oct, 2022

(a month from now)

EP1028111A4 APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

EP1028111A1 APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

EP1028111B1 APGDI Amide Derivatives Or Salts Thereof
Oct, 2018

(3 years ago)

EP2298752A1 APGDI Alpha-Form Or Beta-Form Crystal Of Acetanilide Derivative
Oct, 2022

(a month from now)

EP2298752B1 APGDI Alpha-Form Or Beta-Form Crystal Of Acetanilide Derivative
Oct, 2022

(a month from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7982049 APGDI α-form or β-form crystal of acetanilide derivative Nov, 2023

(1 year, 1 month from now)

US7982049

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

US7342117

(Pediatric)

APGDI α-form or β-form crystal of acetanilide derivative May, 2024

(1 year, 7 months from now)

US10058536 APGDI Pharmaceutical composition containing mirabegron Mar, 2036

(13 years from now)

US10058536

(Pediatric)

APGDI Pharmaceutical composition containing mirabegron Oct, 2036

(14 years from now)

Drugs and Companies using MIRABEGRON ingredient

Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron

Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
8MG/ML FOR SUSPENSION, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.